Low-Cost, Scalable rHSA Production for Pharma & Biotech
Production of Recombinant Human Serum Albumin (rHSA) Using E. coli as an Expression System
Tags: IIT Delhi, India, Healthcare & Lifesciences
A recombinant human serum albumin (rHSA) production process has been developed using E. coli as an expression system, providing a cost-effective and scalable alternative to blood-derived HSA. The optimized process enhances yield by refining intracellular conditions, temperature, induction type, and cell lysis, resulting in a highly functional, soluble protein. Unlike traditional methods relying on blood fractionation or recombinant production in complex hosts, this approach eliminates contamination risks and ethical concerns. The rHSA is biocompatible and functionally equivalent to plasma-derived HSA, making it suitable for pharmaceutical formulations, diagnostics, and cell culture applications. It has been validated at a lab scale with high protein yields and confirmed biocompatibility.
IP Type or Form Factor: Patent Granted; Process & Method
TRL: 4 - minimum viable product built in lab
Industry or Tech Area: Biotechnology; Pharmaceutical Engineering
